- Home
- VRTX vs RELX Comparison
VRTX vs RELX Comparison
Compare VRTX & RELX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRTX
- RELX
- Stock Information
- Founded
- VRTX 1989
- RELX 1903
- Country
- VRTX United States
- RELX United Kingdom
- Employees
- VRTX N/A
- RELX N/A
- Industry
- VRTX EDP Services
- RELX Business Services
- Sector
- VRTX Technology
- RELX Consumer Discretionary
- Exchange
- VRTX Nasdaq
- RELX Nasdaq
- Market Cap
- VRTX 115.6B
- RELX 100.9B
- IPO Year
- VRTX 1991
- RELX N/A
- Fundamental
- Price
- VRTX $436.00
- RELX $55.42
- Analyst Decision
- VRTX Buy
- RELX Strong Buy
- Analyst Count
- VRTX 26
- RELX 2
- Target Price
- VRTX $512.54
- RELX N/A
- AVG Volume (30 Days)
- VRTX 2.1M
- RELX 728.7K
- Earning Date
- VRTX 05-05-2025
- RELX 07-24-2025
- Dividend Yield
- VRTX N/A
- RELX 1.01%
- EPS Growth
- VRTX N/A
- RELX 10.15
- EPS
- VRTX N/A
- RELX 1.29
- Revenue
- VRTX $11,099,700,000.00
- RELX $11,810,658,884.00
- Revenue This Year
- VRTX $10.36
- RELX $9.12
- Revenue Next Year
- VRTX $10.61
- RELX $7.22
- P/E Ratio
- VRTX N/A
- RELX $42.12
- Revenue Growth
- VRTX 8.98
- RELX 2.98
- 52 Week Low
- VRTX $377.85
- RELX $43.28
- 52 Week High
- VRTX $519.88
- RELX $55.68
- Technical
- Relative Strength Index (RSI)
- VRTX 39.81
- RELX 63.61
- Support Level
- VRTX $416.60
- RELX $54.54
- Resistance Level
- VRTX $448.00
- RELX $55.58
- Average True Range (ATR)
- VRTX 13.25
- RELX 0.50
- MACD
- VRTX -0.20
- RELX 0.01
- Stochastic Oscillator
- VRTX 37.85
- RELX 94.18
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
About RELX RELX PLC PLC
RELX is a global provider of information-based analytics and decision tools for professional and business customers in various industries. The company serves sectors such as science and medical research, risk management, and legal. In addition, RELX organizes large-scale digital and face-to-face events such as industry trade shows. Around 60% of revenue is generated in North America and about 20% in Europe.